ARTESIA Trial Summary The ARTESIA trial, which stands for “Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation,” was a landmark study aimed at comparing the efficacy and safety of apixaban versus aspirin in patients with subclinical atrial fibrillation (AF). The … Read More
Blog
COSMIC-313 Trial: Cabozantinib in Renal Cell Cancer
The COSMIC-313 Trial: A New Frontier in Renal-Cell Carcinoma Treatment In the landscape of oncology, renal-cell carcinoma stands as a formidable challenge, often presenting at advanced stages and with a dire need for effective treatments. Enter the COSMIC-313 Trial, a … Read More
DAPA-MI Trial: Dapagliflozin in MI
DAPA-MI Trial: Dapagliflozin in MI? The DAPA-MI Trial, as reported in the New England Journal of Medicine in 2023, was a randomized, double-blind clinical trial designed to assess the safety and efficacy of dapagliflozin, a medication typically used to treat … Read More
ELATIVE Trial: Elafibranor in PBC
Title: ELATIVE Trial: A Landmark Study on Elafibranor’s Efficacy in Primary Biliary Cholangitis Introduction:The medical community has taken a significant step forward with the recent ELATIVE Trial, a study that rigorously evaluates the efficacy and safety of Elafibranor in patients … Read More
CASTLE HTx Trial: Ablation in HF and AFib
The CASTLE HTx trial, as published in the New England Journal of Medicine in 2023, was a single-center, open-label trial that aimed to determine the potential therapeutic effect of catheter ablation for symptomatic atrial fibrillation (AF) in patients with end-stage … Read More
BEAM-BD Trial: Antidepressants in Bipolar 1 Depression
The BEAM-BD trial, as presented in the New England Journal of Medicine in 2023, was a multisite, double-blind, randomized, placebo-controlled trial with the objective of comparing the maintenance of treatment with adjunctive escitalopram or bupropion XL versus discontinuation of antidepressant … Read More
ADVENT Trial: Pulse Field Ablation for AFib
The ADVENT trial, published in the New England Journal of Medicine in 2023, was a randomized, single-blind, noninferiority trial designed to compare the safety and efficacy of pulsed field ablation with conventional thermal ablation techniques (radiofrequency or cryoballoon) for the … Read More
TGC-Fast Trial: Tight Glucose Control in ICU
The TGC-Fast Trial, featured in the New England Journal of Medicine in 2023, was a multicenter, randomized, controlled trial that aimed to assess the benefits of tight glucose control without early parenteral nutrition in the intensive care unit (ICU). The … Read More
Target-HTN trial: Lorundrostat in Hypertension
The TARGET-HTN trial, published in JAMA in September 2023, investigated the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in treating patients with uncontrolled hypertension. This randomized, placebo-controlled, dose-ranging trial included 200 patients who were adults with uncontrolled hypertension … Read More
OCTOBER Trial: OCT in Complex PCI
The OCTOBER trial, detailed in the New England Journal of Medicine in 2023, was a multicenter, randomized, open-label trial designed to assess the effectiveness of optical coherence tomography (OCT) in guiding percutaneous coronary intervention (PCI) for the treatment of complex … Read More